| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/05/2011 | EP2269620A1 Therapeutic uses of dunaliella powder |
| 01/05/2011 | EP2269613A2 Solid orald dosage form comprising a combination of metformin and glibenclamide |
| 01/05/2011 | EP2269612A1 Eye-drop preparation and use thereof |
| 01/05/2011 | EP2269611A2 EP2 and EP4 agonists as agents for the treatment of influenza A viral infection |
| 01/05/2011 | EP2269610A2 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| 01/05/2011 | EP2269609A2 Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
| 01/05/2011 | EP2269608A2 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
| 01/05/2011 | EP2269607A1 Trigonelline as a muscle stimulant |
| 01/05/2011 | EP2269606A2 Transdermal analgesic systems having reduced abuse potential |
| 01/05/2011 | EP2269605A2 Methylphenidate Modified Release Formulations |
| 01/05/2011 | EP2269604A1 Treatment of solid tumours with rapamycin derivatives |
| 01/05/2011 | EP2269603A1 Treatment of solid tumours with rapamycin derivatives |
| 01/05/2011 | EP2269602A1 Antibiotic compositions for treatment of the eye, ear and nose |
| 01/05/2011 | EP2269601A1 LR-9, LR-74 and LR-90 for use in treating complications resulting from diabetes |
| 01/05/2011 | EP2269600A1 Treatment of sleep disorders using eplivanserin in COPD patients |
| 01/05/2011 | EP2269599A1 Chemically stable compositions of 4-hydroxy tamoxifen and their therapeutical applications |
| 01/05/2011 | EP2269598A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 01/05/2011 | EP2269597A1 CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
| 01/05/2011 | EP2269596A2 Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders |
| 01/05/2011 | EP2269595A1 Titratable dosage transdermal delivery system |
| 01/05/2011 | EP2269593A1 Transdermally absorbable preparation |
| 01/05/2011 | EP2269592A1 Pharmaceutical composition of micronised progesterone and its use |
| 01/05/2011 | EP2269591A2 Improved pharmaceutical formulations |
| 01/05/2011 | EP2269590A2 Ion binding polymers and uses thereof |
| 01/05/2011 | EP2269589A2 Ion binding polymers and uses thereof |
| 01/05/2011 | EP2269588A1 Medicinal tablet with prolonged release of the active agent |
| 01/05/2011 | EP2269587A1 Controlled release hydrocodone formulations |
| 01/05/2011 | EP2269585A2 Once-a-day oxycodone formulations |
| 01/05/2011 | EP2269584A1 Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
| 01/05/2011 | EP2269583A1 Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
| 01/05/2011 | EP2269582A2 Multiparticulates of preferably an opioid, and method of manufacturing using extrusion |
| 01/05/2011 | EP2269581A1 Improvements relating to biocidal compositions |
| 01/05/2011 | EP2269580A2 Compositions comprising camptothecins in microspheres |
| 01/05/2011 | EP2269579A2 Tamper-resistant products for opioid delivery |
| 01/05/2011 | EP2269577A2 Injectable suspensions having improved injectability properties |
| 01/05/2011 | EP2269576A2 A Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 01/05/2011 | EP2269575A1 Method for improving bioavailability of latanoprost |
| 01/05/2011 | EP2269574A2 Implants for administering substances and methods of producing implants |
| 01/05/2011 | EP2269572A1 Polymeric compositions comprising crystalline therapeutic agents and their preparations |
| 01/05/2011 | EP2269468A1 NMP-enriched extract |
| 01/05/2011 | EP2269467A1 Pasteurisation process for microbial cells and microbial oil |
| 01/05/2011 | EP2269444A2 DSRNA as insect control agent |
| 01/05/2011 | EP2268812A1 Inhibitors of stim1 for the treatment of cardiovascular disorders |
| 01/05/2011 | EP2268654A2 Selective high-affinity polydentate ligands and methods of making such |
| 01/05/2011 | EP2268653A2 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds, and the use thereof |
| 01/05/2011 | EP2268652A2 Platinum-n-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof |
| 01/05/2011 | EP2268648A1 Crystalline (6r,7r)-7-{2-(5-amino-ý1,2,4¨thiadiazol-3-yl)-2-ý(z)-trityloxyimino¨-acetylamino}-3-ý(r)-1'-tert-butoxycarbonyl-2-oxo-ý1,3'¨bipyrrolidinyl-(3e)-ylidenemethyl¨-8-oxo-5-thia-1-aza-bicycloý4.2.0¨oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use |
| 01/05/2011 | EP2268647A2 Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders |
| 01/05/2011 | EP2268646A2 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase |
| 01/05/2011 | EP2268645A1 Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur |
| 01/05/2011 | EP2268644A1 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| 01/05/2011 | EP2268643A1 Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors |
| 01/05/2011 | EP2268642A1 1' -substituted carba-nucleoside analogs for antiviral treatment |
| 01/05/2011 | EP2268641A2 Heterocyclic compounds as adenosine receptor antagonist |
| 01/05/2011 | EP2268639A2 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| 01/05/2011 | EP2268638A1 Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
| 01/05/2011 | EP2268637A1 Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors |
| 01/05/2011 | EP2268636A1 Gamma secretase modulators |
| 01/05/2011 | EP2268634A2 Processes for the preparation of bosentan and related compounds using novel intermediates |
| 01/05/2011 | EP2268633A1 Pyridazinone glucokinase activators |
| 01/05/2011 | EP2268632A1 Tertiary amine derivatives as phosphodiesterase-4 inhibitors |
| 01/05/2011 | EP2268631A1 Aminopiperidinyl derivatives and uses thereof |
| 01/05/2011 | EP2268628A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| 01/05/2011 | EP2268626A1 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of hsp90 chaperone and the intermediates for production thereof |
| 01/05/2011 | EP2268625A1 Oxo-heterocyclic substituted carboxylic acid derivates and the use thereof |
| 01/05/2011 | EP2268623A1 Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| 01/05/2011 | EP2268618A1 Compounds and compositions as tlr activity modulators |
| 01/05/2011 | EP2268616A1 Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| 01/05/2011 | EP2268613A2 Inhibitors of cell proliferation and uses thereof |
| 01/05/2011 | EP2268612A1 Arylsulfonamide-based matrix metalloprotease inhibitors |
| 01/05/2011 | EP2268606A1 4-dimethylaminobutyric acid derivatives |
| 01/05/2011 | EP2268605A1 Fatty acid derivatives for oral administration endowed with high paia- tability |
| 01/05/2011 | EP2268604A1 Therapies for cancer using isotopically substituted lysine |
| 01/05/2011 | EP2268603A1 Process for the preparation of 2-amino-2- [2- (4-c3-c21-alkyl-phenyl)ethyl]propane-1, 3-diols |
| 01/05/2011 | EP2268600A1 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions |
| 01/05/2011 | EP2268320A1 Image-guided therapy of myocardial disease: composition, manufacturing and applications |
| 01/05/2011 | EP2268292A2 Method and compositions for treatment of cancer |
| 01/05/2011 | EP2268290A2 Styrene maleic anhydride based formulation for male contraception and prostate cancer |
| 01/05/2011 | EP2268289A1 Anti-infective agents and uses thereof |
| 01/05/2011 | EP2268288A2 Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| 01/05/2011 | EP2268287A1 Methods of administering antitumor agent comprising deoxycytidine derivative |
| 01/05/2011 | EP2268286A1 Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation |
| 01/05/2011 | EP2268285A1 Therapeutic compounds |
| 01/05/2011 | EP2268284A2 Use of g-rich oligonucleotides for treating neoplastic diseases |
| 01/05/2011 | EP2268283A2 Oral modified-release formulations containing thiazepines |
| 01/05/2011 | EP2268282A1 Liquid formulation for deferiprone with palatable taste |
| 01/05/2011 | EP2268281A1 Thienopyrroles and pyrrolothiazoles as new therapeutic agents |
| 01/05/2011 | EP2268280A2 Quinolizidinone m1 receptor positive allosteric modulators |
| 01/05/2011 | EP2268279A1 Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl¨-3-oxoisoindoline-4-yl}carboxamide |
| 01/05/2011 | EP2268278A1 Pharmaceutical composition |
| 01/05/2011 | EP2268277A1 Use of flavonoide compounds for the propyhylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases |
| 01/05/2011 | EP2268276A1 Compositions for the treatment and prevention of infections of the oral cavity |
| 01/05/2011 | EP2268275A2 Antimicrobials having polyquarternary ammoniums and alcohol-bearing amidoamines and methods for their use |
| 01/05/2011 | EP2268274A2 Vitamin e derivatives and their uses |
| 01/05/2011 | EP2268273A1 Small-molecule modulators of trp-p8 activity |
| 01/05/2011 | EP2268272A2 Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof |
| 01/05/2011 | EP2268270A2 Improved formulations for poorly permeable active pharmaceutical ingredients |
| 01/05/2011 | EP2268268A2 Orally disintegrating compositions of rhein or diacerein |
| 01/05/2011 | EP2268265A2 Compositions for site-specific delivery of imatinib and methods of use |
| 01/05/2011 | EP2268160A1 Emulsions including a peg-derivative of tocopherol |